Clinical Trial

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-05-07; most recent amendment 2026-04-15.
Status change: Recruiting → Active, Not Recruiting 2026-04-15
Status change: Not Yet Recruiting → Recruiting 2025-06-23
Trial Details
NCT Number NCT06972472
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight, Type 2 Diabetes
Enrollment 600 participants
Start Date 2025-05-19
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-20